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Strategies to Optimize Drotrecogin alfa (activated) Use:
Guidelines and Therapeutic Controversies
Henry Cohen, Pharm.D., and Lynda S. Welage, Pharm.D., FCCP
Drotrecogin alfa (activated) is a new agent that may substantially affect the
treatment of patients with severe sepsis.  Despite its therapeutic promise,
treatment with drotrecogin alfa (activated) represents a new challenge for
many clinicians and health care centers.  Specifically, optimizing the
appropriate role for drotrecogin alfa (activated) requires balancing numerous
issues, including its efficacy in high-risk patients with its potential for
indiscriminate administration.  One common approach to minimizing
indiscriminate administration of drotrecogin alfa (activated) and maximizing
its efficacy while minimizing its toxicity is for hospitals to develop therapeutic
guidelines that define how the agent should be used.  We outline factors that
should be considered when developing drotrecogin alfa (activated) therapy
guidelines and address realistic questions that routinely arise in clinical
practice regarding the implementation of such guidelines and the
administration of this product.  In general, the guidelines must facilitate
optimization of drug therapy and not be viewed as hurdles to drug therapy.
Developing clear guidelines that are based on evidence, outlining a specific
process to facilitate optimal therapy, and educating all parties involved are
paramount to ensuring that the benefits of therapy are maximized.
(Pharmacotherapy 2002;22(12 Pt 2):223S–235S)
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Successful Implementation of the Guidelines
The mortality rate associated with severe sepsis
may approach 50%, with an annual cost burden
to society of approximately $17 billion.1, 2
Drotrecogin alfa (activated) (Xigris; Eli Lilly and
Company, Indianapolis, IN) is a new agent that
may substantially affect the treatment of patients
with severe sepsis.  The Recombinant Human
Activated Protein C Worldwide Evaluation in
Severe Sepsis (PROWESS) trial demonstrated an
absolute reduction in the risk of death of 6.1%.3
On November 21, 2001, drotrecogin alfa
(activated)  received approval by the United
States Food and Drug Administration (FDA) for
reducing mortality in adult patients with severe
sepsis who have a high risk of death.4, 5 This is
the first drug to receive FDA approval for the
management of severe sepsis.
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Despite its therapeutic promise, treatment with
drotrecogin alfa (activated) represents a new
challenge for many clinicians and health care
centers.  For example, the acquisition cost of
drotrecogin alfa (activated) is substantial and,
thus, may have a considerable impact on the
hospital pharmacy’s drug budget.6 Furthermore,
based on results of the PROWESS trial, drotre-
cogin alfa (activated) has been proven to reduce
mortality for patients who are at a high risk of
death from severe sepsis.3 Nonetheless, as in
many clinical trials, stringent inclusion and
exclusion criteria were used.3 Thus, extrapola-
tion of the results to routine clinical practice is
somewhat difficult and has led to many thera-
peutic questions.  Specifically, concerns exist
regarding its safety in routine clinical practice, as
well as its efficacy in less severely ill populations.
Moreover, the diagnosis of severe sepsis is
somewhat difficult, making the identification of
optimal candidates for drotrecogin alfa
(activated) therapy a challenge.  Optimizing the
appropriate administration of drotrecogin alfa
(activated) requires a careful balance among
numerous issues, including its efficacy in high-
risk patients with the potential for indiscriminate
administration.  One common approach to
minimizing indiscriminate administration of
drotrecogin alfa (activated) and maximizing its
efficacy while minimizing its toxicity is for
hospitals to develop therapeutic guidelines that
define how the agent should be administered.
Guidelines can take on various forms.  Drug
use guidelines outline how a given agent should
be administered, and treatment guidelines outline
how a given disease state should be managed.7 In
both cases, guidelines are educational tools that
can be used as part of the formulary management
system.  We outline factors that should be con-
sidered when developing guidelines for admin-
istering drotrecogin alfa (activated) therapy and
provide a template for institutions to use when
developing their own guidelines (Appendix 1).
Moreover, we address several realistic questions
that routinely arise in clinical practice regarding
the implementation of such guidelines and/or the
administration of this product.
As with the development of other drug
administration guidelines, all parties who are
considered stakeholders must be involved in the
development of the guidelines, as this creates
buy-in.8 Although the specific individuals
involved in the development of drotrecogin alfa
(activated) administration guidelines will likely
vary from institution to institution, a multi-
disciplinary approach should be used.  In
general, intensivists, infectious disease
specialists, pulmonologists, surgeons,
pharmacists, and nurses should be included in
the decision-making process.  Others individuals,
depending on institutional practices, may be
involved in developing the guidelines, such as
other specialty physicians, risk management
personnel, ethicists, and various administrators,
which may include the medical director, chief
financial officer, and the chairman of the
pharmacy and therapeutics committee.  For the
guidelines to be used as an effective formulary
management tool, the hospital’s pharmacy and
therapeutics committee should approve the
drotrecogin alfa (activated) administration
guidelines formally and develop a process for
ensuring successful implementation of the
guidelines.
Numerous factors should be considered when
developing drotrecogin alfa (activated) adminis-
tration guidelines.  In general, the guidelines
should identify which patients are candidates for
the product and when the product should be
administered.  In addition, they should outline
specific contraindications and/or warnings
regarding drotrecogin alfa (activated) therapy in
certain circumstances.  The committee developing
the guidelines should be encouraged to develop
additional educational tools that can facilitate
appropriate administration, such as dosing
guidelines, monitoring guidelines, and drug and
severe sepsis monographs.  As much as possible,
an evidence-based decision-making process
should be used to develop the guidelines.8
Unfortunately, many questions remain unanswered
regarding drotrecogin alfa (activated) therapy,
and as a result, clinicians must extrapolate
information from other circumstances.  The
therapeutic questions that may arise in routine
clinical practice regarding the administration of
this product and/or the implementation of the
guidelines represent therapeutic challenges for all
clinicians, as no definitive data exist.  As science
evolves and our understanding of the safety and
efficacy of drotrecogin alfa (activated) expands,
answers will emerge to these therapeutic
challenges.  In the meantime, however, all of us
are faced with extrapolating data and using our
best clinical judgment.
Factors to Consider in Developing Guidelines
From a simplistic standpoint, when developing
guidelines to optimize drug administration, one
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should identify who should receive the agent,
when the agent should be administered to
optimize success, how the agent should be
administered (e.g., dosage, route of adminis-
tration), who should not receive the agent or in
whom one should carefully weigh the potential
risks versus benefits, monitoring parameters, and
factors that may affect the safety and/or efficacy
of the agent.  Although a template of drug
administration guidelines has been included in
Appendix 1, clinicians must understand the
issues surrounding each of these decision-making
steps, since guidelines at individual institutions
may vary depending on interpretation of the
available data.
Diagnostic Criteria:  Defining Who Should
Receive Drotrecogin alfa (activated)
Drotrecogin alfa (activated) is indicated for
adult patients with severe sepsis who are at high
risk of death.5 Intuitively, this statement seems
to accurately define who should receive this
drug.  Unfortunately, on closer examination,
many issues need to be considered when
developing criteria that determine which patients
should receive drotrecogin alfa (activated).
Defining Severe Sepsis:  Pitfalls of SIRS Criteria
The systemic inflammatory response syndrome
(SIRS) is defined as a systemic inflammatory
response to a variety of clinical insults,
manifested by two or more of the following:
temperature higher than 38°C or lower than
36°C, heart rate greater than 90 beats/minute,
respiratory rate greater than 20 breaths/minute or
partial pressure of carbon dioxide (PCO2) less
than 32 mm Hg, or a white blood cell count
greater than 12 x 103/mm3 or less than 4 x
103/mm3 or greater than 10% immature forms
(bands).9, 10 Severe sepsis is defined as the
systemic inflammatory response to infection,
with the presence of organ dysfunction, hypo-
perfusion, or hypotension.9, 10 The PROWESS
trial used modified and more stringent SIRS
criteria; the study required patients to meet at
least three (rather than two) SIRS criteria for
diagnosis.3 Although the modified SIRS criteria
may be more sensitive or specific, this approach
has not been validated.  In addition, SIRS criteria
regarding core temperature, heart rate, and white
blood cell count may inadvertently exclude
certain patients who are in fact septic.  In the
geriatric population, in which severe sepsis is
most prevalent, a core temperature of 38°C or
greater ( ‡ 100.4°F) may not be prominent.11
Many elderly patients, who have lower than
normal baseline body temperatures, experience a
spike in response to infection that does not exceed
38°C.  In some cases, the criterion of a heart rate
of 90 beats/minute or greater may not be met
owing to disease- (e.g., hypothyroidism) and
drug-induced suppression of heart rate.
Occasionally, cachectic elderly patients with
comorbid conditions such as diabetes and
chronic obstructive pulmonary disease are unable
to mount an infection-induced increase in white
blood cells that exceeds 12 x 103/mm3.12 In
addition, although a differential showing greater
than 10% bands is one criterion for SIRS, because
of the lack of laboratory sensitivity and
specificity in determining the immature band
count, many institutions no longer routinely
perform this test as part of a complete blood
count.13
Defining High Risk of Death
As previously stated, the FDA has approved
drotrecogin alfa (activated) for the reduction of
mortality in adult patients with severe sepsis
(sepsis associated with acute organ dysfunction)
who have a high risk of death (e.g., as determined
by the Acute Physiology and Chronic Health
Evaluation [APACHE] II scoring system).5 In the
PROWESS trial, the APACHE II scores were
calculated from physiologic and laboratory data
obtained within the 24-hour period immediately
before drotrecogin alfa (activated) administration,
irrespective of the preceding length of stay in the
intensive care unit.3 The highest score for each
component of the APACHE II was used for data
analysis.  The mean APACHE II score in the
patients who received drotrecogin alfa (activated)
was 25 ± 7.8.  Patients with APACHE II scores in
the first and second quartiles (scores 3–24) did
not have an absolute mortality reduction
compared with the placebo group.  However,
patients with APACHE II scores in the third and
fourth quartiles (scores 25–53) achieved a 13%
absolute mortality difference relative to the
placebo group.  The manufacturer indicates that
APACHE II scores were most effective in
determining the patients who were most likely to
benefit from drotrecogin alfa (activated) therapy.5
However, the manufacturer also mentions that
other indicators of the severity of illness, such as
number of organ failures, were predictive in
determining the patients who were most likely to
benefit from drotrecogin alfa (activated) therapy.
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Patients with one, two, three, and four or more
organ failures experienced absolute reductions in
mortality of 2%, 5%, 8%, and 11%, respectively.5
When developing guidelines for drotrecogin
alfa (activated), one must decide how the
institution will identify patients who are at high
risk of death from severe sepsis.  The two most
common approaches involve determining
APACHE II scores or number of organ failures.
The APACHE II scoring process can be highly
subjective, error prone, and labor and time
intensive.14 Determining who will perform the
APACHE II scoring and when and how often it
will be performed, and deciding how to interpret
divergent scoring by different clinicians may be
an arduous and unrealistic task.  For example, an
APACHE II score of 23 versus 25 may be the
deciding factor on who will receive therapy.  Note
that the APACHE II scoring system was not
validated to this degree of sensitivity.  For each 5-
point increase in APACHE II score, there is a
significant increase in the risk of death.15
However, attempting to distinguish between
patients whose scores are within 4 points of each
other is nebulous.15 Therefore, using the number
of organ failures as the absolute criterion for
determining candidates for drotrecogin alfa
(activated) therapy instead of the APACHE II
scoring system may be a more practical approach.
To maximize benefit and curtail drug
acquisition costs, many institutions use two
organ failures as the minimal criterion, although
some institutions have opted to use one organ
failure.  The decision to establish two organ
failures as the minimal criterion for drotrecogin
alfa (activated) therapy often relates to the fact
that in the PROWESS trial patients with two
organ failures (75% of the trial population) had
an absolute reduction in the risk of death of 5%,
which is similar to the overall results experienced
in the trial (i.e., 6% absolute risk reduction).
Thus, although not perfect, the number of organ
systems failing becomes a surrogate for severity
of illness.  This approach may be more pragmatic,
particularly when making therapeutic decisions
regarding administration of drotrecogin alfa
(activated) at the bedside.  However, the type of
organ dysfunction must be identified to be
considered as part of the criterion.
In the PROWESS trial, drotrecogin alfa
(activated) was administered to patients with
severe sepsis and at least one associated acute
organ dysfunction.3 Acute organ dysfunction
included any one of the following five criteria:
cardiovascular, renal, respiratory, or hematologic
dysfunction, or unexplained metabolic acidosis.
Of note, several other acute organ dysfunctions
were not part of the PROWESS criteria, including
hepatic (e.g., jaundice, elevated liver enzymes),
central nervous system (e.g., psychosis, delirium,
coma), endocrine (e.g., hyperglycemia, hyper-
triglyceridemia), and gastrointestinal (e.g.,
bleeding, perforation, ileus).  The drotrecogin
alfa (activated) guidelines depicted in Appendix
1 include only the organ dysfunctions from the
PROWESS trial.
Time Frame for Diagnosis and Administration
In the pivotal trial that spawned the approval
of drotrecogin alfa (activated) (the PROWESS
trial), patients were eligible to receive drotrecogin
alfa (activated) if they met the criteria for severe
sepsis that lasted no longer than 24 hours from
the time of screening.3 Subsequently, drotrecogin
alfa (activated) therapy had to be started within
24 hours after they met the inclusion criteria.
The mean time from first organ dysfunction to
the start of drotrecogin alfa (activated) therapy
was 17.4 ± 9.1 hours.  Theoretically, the
methodology in the PROWESS trial permitted a
maximum of a 48-hour window from screening
and severe sepsis onset to drug administration.
Based on the data from the PROWESS study,
guidelines regarding drotrecogin alfa (activated)
therapy should state clearly the time frame for
establishing the required diagnostic criteria and
administering the product (i.e., meeting
diagnostic criteria within 48 hrs of drug
administration).  Although some clinicians may
take the approach of waiting until nearing the
48-hour deadline to administer the agent, this
approach is ill advised and not recommended
because the sepsis cascade is a vicious and
relentless cycle with high mortality.  Similarly, in
cases in which retrospective assessment suggests
that the severe sepsis developed several days
previously (> 48 hrs), administration of
drotrecogin alfa (activated) is not advised
because no data exist to support its efficacy.  The
latter situation (> 48 hrs), however, often
represents an ethical controversy because
although no data exist to support the efficacy of
drotrecogin alfa (activated), there is no
therapeutic alternative.  Although individual
situations may be managed differently, the
committee developing drotrecogin alfa
(activated) guidelines should delineate the
general approach that will be recommended to
practitioners.
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Weighing Risks versus Benefits:  Identifying
Contraindications or Warnings
In addition to identifying who should receive
drotrecogin alfa (activated), the drug
administration guidelines should identify who
should not receive the agent and identify
populations in whom the decision to administer
drotrecogin alfa (activated) must be weighed
carefully against its risks.  These decisions can be
classified broadly as identifying contraindications
and/or warnings involving drotrecogin alfa
(activated) in certain populations.  In general,
these situations may affect the patient’s safety, or
no data are available to support the efficacy.
Because drotrecogin alfa (activated) is a recom-
binant form of the body’s natural anticoagulant,
activated protein C, it may increase the risk of
serious bleeding events.  Owing to the risk of
bleeding and the associated high risk of death or
significant morbidity, the manufacturer states
that drotrecogin alfa (activated) is contra-
indicated in patients with active bleeding, recent
(within 3 mo) hemorrhagic stroke, recent (within
2 mo) intracranial or intraspinal surgery or
severe head trauma, trauma with an increased
risk of life-threatening bleeding, presence of an
epidural catheter or intracranial neoplasm or
mass lesion, or evidence of cerebral herniation.5
In addition, drotrecogin alfa (activated) is
contraindicated in patients with known
hypersensitivity to the drug or any component of
it.5 However, many patients who were at risk for
potential bleeding were excluded from the
pivotal trial; therefore, safety and efficacy data are
lacking for these patients.3 Specifically, in the
PROWESS trial, to minimize the risk of bleeding,
the exclusion criteria for patients who may be at
a higher risk of bleeding was comprehensive and
included many scenarios that are not included in
the manufacturer’s contraindications.3, 5
Because of the risk of bleeding, some
clinicians have opted to use the PROWESS
exclusion criteria in patients at an increased risk
of bleeding as absolute contraindications.  The
guidelines depicted in Appendix 1 list the
PROWESS exclusion criteria, similar to the FDA-
approved manufacturer’s labeling of warnings,
requiring the clinician to evaluate the anticipated
benefits of drotrecogin alfa (activated) carefully
against the risks.  The final choice in
administering drotrecogin alfa (activated) despite
one or more bleeding risks is at the clinician’s
discretion.  In the PROWESS trial, patients were
excluded for specific criteria including a futile
diagnosis, increased risk of bleeding, and a
known hypercoagulable condition (Appendix 1,
section IV)3; however, these specific criteria are
not mentioned in the FDA-approved manufac-
turer’s labeling.5 Hence, the clinician must weigh
the benefits of drotrecogin alfa (activated)
therapy carefully against the risks in patients
with these scenarios.
Some of the PROWESS trial exclusionary
criteria may not be clinically relevant.  For
example, although patients weighing more than
135 kg were excluded from the PROWESS trial,
this was done only to ensure an adequate supply
of the drug.  Nevertheless, a paucity of reported
pharmacokinetic, efficacy, and safety data exists
in patients with severe sepsis who weigh more
than 135 kg.  Pharmacokinetics are linear from
3–133 kg at the recommended dosage of 24
µg/kg/hour.
Alternatively, some of the PROWESS trial
exclusionary criteria may be clinically relevant,
such as chronic renal failure requiring
hemodialysis or peritoneal dialysis because of
disease-induced decreased platelet aggregation
and an inherent risk of bleeding.  Indeed, a
retrospective analysis of the Efficacy and Safety of
Subcutaneous Enoxaparin in Non–Q-Wave
Coronary Events (ESSENCE) and Thrombolysis
in Myocardial Infarction (TIMI) 11B trials found
that the administration of heparin or low-
molecular-weight heparin in patients with
chronic renal failure was associated with a 6-fold
increase in the occurrence of serious bleeding
events and a trend toward an increase in
composite end points (death, myocardial
infarction, and recurrent angina).16 Since data
regarding drotrecogin alfa (activated)’s efficacy
and risk of bleeding in patients with chronic
renal failure who are receiving dialysis treatments
have not been studied, the potential risks and
benefits of therapy must be weighed carefully in
these patients.  Patients with acute renal failure
requiring dialysis were excluded in the
PROWESS trial.  Finally, known hypercoagulable
conditions such as resistance to activated protein
C may blunt or eliminate the efficacy of
drotrecogin alfa (activated).  In the PROWESS
trial, however, patients who were not protein C
deficient (95 patients) realized similar mortality
benefits compared with those who were protein
C deficient (605 patients).3 Data regarding the
efficacy of drotrecogin alfa (activated) in patients
with known hypercoagulable states do not exist.
One strategy for dealing with these situations as
part of the guidelines and ordering process, as
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outlined in Appendix 1, is to require the clinician
to acknowledge such situations (i.e., the
PROWESS exclusion criteria not mentioned in
the FDA-approved product labeling) and
determine whether there is benefit to drotrecogin
alfa (activated) therapy relative to the risk of
bleeding and/or high cost.
Placing the Risk of Bleeding into Perspective
During the 96-hour infusion period in the
PROWESS trial, the frequency of serious bleeding
events was 2.4% with drotrecogin alfa (activated)
and 1% with placebo, which is both clinically and
statistically significant (p=0.024).3 Conversely,
during the 28-day study observation period, the
frequency of serious bleeding events was 3.5%
with drotrecogin alfa (activated) and 2% with
placebo (p=0.060).3 In the PROWESS trial,
serious bleeding was defined as any intracranial
hemorrhage, any life-threatening bleeding, any
bleeding event classified as serious by the
investigator, or any bleeding that required
administration of more than 3 units of blood on 2
consecutive days.  Despite the risk of serious
bleeding events, benefits of drotrecogin alfa
(activated) therapy were realized.  Indeed, many
trials for acute coronary syndromes in which
several agents that alter the coagulation profile
(e.g., aspirin, heparin, low-molecular-weight
heparins, glycoprotein IIb-IIIa inhibitors) were
administered yielded statistically significant
benefits despite the added occurrence of serious
bleeding events.  Theoretically, administering
drotrecogin alfa (activated) in patients with a
predisposing bleeding risk may increase the
frequency of serious bleeding events.  Whether
the benefits of administering drotrecogin alfa
(activated) in these settings will outweigh the
risk has not been studied.  Patients with overt
disseminated intravascular coagulopathy had an
absolute reduction of mortality of 23% yet no
increase in bleeding.  One noteworthy point is
that in the PROWESS trial the reductions in
mortality and the frequency of a serious bleeding
event were similar in patients receiving prophy-
lactic dosages of heparin (≤ 15,000 U/day) or
no heparin (24.92% vs 24.07% and 2.37% vs
2.31%, respectively).3 Serious bleeding with
drotrecogin alfa (activated) therapy occurred
predominantly during  infusion.
From the anticoagulant literature, the risk of
bleeding is related to the intensity of anticoag-
ulation therapy or anticoagulant response,
patient characteristics, concomitant therapy, and
duration of anticoagulant administration.17
Although the definition of major bleeding varies
slightly among anticoagulant trials and is
different than that used in the PROWESS trial,
the American College of Chest Physicians
(ACCP) defines bleeding as major if it was
intracranial or retroperitoneal or if it led directly
to death or resulted in hospitalization or
transfusion.17, 18 With use of the ACCP
definition, the rates of major bleeding associated
with intravenous unfractionated heparin were
0–7%, with the rates of fatal bleeding being
0–2%.18 For low-molecular-weight heparin, the
rates of major bleeding were reported to be 0–3%,
with the rates of fatal bleeding ranging from
0–0.8%.17 These data place into clinical
perspective the risk of major bleeding for
drotrecogin alfa (activated) relative to that of
other agents that alter the coagulation profile and
are commonly given to critically ill patients.  The
risk of serious bleeding as identified in the
PROWESS study is similar or lower than the risk
commonly observed with therapeutic heparin;
however, one must be cognizant that the
definitions for major bleeding were significantly
different.3, 17 The rates of intracranial
hemorrhage observed in the PROWESS trial and
open-label studies (0.2–1%) are similar to that
observed during long-term warfarin therapy
(0.2–1.8%).3, 17
Extrapolating Lessons Learned with Other
Anticoagulants 
The rate of bleeding associated with heparin is
influenced by the dosage of heparin and the
subsequent anticoagulant response.17 Bleeding is
more likely to occur when an in vitro test of
response (such as activated partial thrombo-
plastin time [aPTT]) is prolonged excessively.
However, bleeding can occur even when the in
vitro test of response is in the therapeutic range.
In addition, drotrecogin alfa (activated) may
variably prolong aPTT, and thus aPTT cannot be
used reliably to assess the degree of coagulation
or coagulopathy or to predict bleeding risk.5 The
effect of drotrecogin alfa (activated) on aPTT
depends in part on how quickly the sample is
assayed.  Patients with severe sepsis often have a
coagulopathy (independent of drug administration)
that is associated with prolongation of aPTT and
prothrombin time.  Prothrombin time is not
affected by drotrecogin alfa (activated) and can
be used to monitor the patient’s underlying
coagulopathy.
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There is also evidence from the anticoagulation
literature that comorbid conditions such as
recent surgery, recent trauma, or concomitant
antiplatelet therapy increase the risk of
bleeding.17 Although these high bleeding risk
situations can be considered as either warnings
or contraindications to drotrecogin alfa
(activated) therapy, in the clinical arena one often
is faced with therapeutic challenges.  For
example, patients with severe thrombocytopenia
are at an increased risk of bleeding.  The
PROWESS trial excluded patients with platelet
counts less than 30 x 103/mm3.  However, the
following question likely will arise:  Should a
patient with thrombocytopenia and severe sepsis
receive drotrecogin alfa (activated)?  Since no
direct evidence is available to quantify the
additional bleeding risk of administering
drotrecogin alfa (activated) to a patient with a
low platelet count, one must weigh the risks and
benefits of this situation carefully.  However,
patients receiving drotrecogin alfa (activated)
who had baseline platelet counts less than 50 x
103/mm3 had a lower mortality rate compared
with that of the placebo group (25% vs 63%,
respectively).19 Similarly, in the PROWESS study,
platelet counts decreased to less than 30 x
103/mm3 within the first 5 study days in 34
patients receiving either drotrecogin alfa
(activated) or placebo.  The patients receiving
drotrecogin alfa (activated) had a lower mortality
rate (33%) compared with that of the placebo
group (84%).19
Another common clinical scenario not studied
in the PROWESS trial that is encountered in
clinical practice poses the following question:
Should antiplatelet agents, with the exception of
aspirin at dosages less than 650 mg/day, be
discontinued when drotrecogin alfa (activated) is
started or do antiplatelet agents preclude
administration of drotrecogin alfa (activated)?
Although the risk of bleeding associated with
heparin increases with concomitant aspirin
administration, this combination commonly is
given in the initial treatment of acute coronary
artery syndromes, with benefit and without
serious bleeding.17 Furthermore, because the
effects of aspirin persist (7 days) for longer than
the maximum 4-day infusion time of drotrecogin
alfa (activated), discontinuation of aspirin before
drotrecogin alfa (activated) may not minimize the
risk of bleeding.  Similarly, although the risk of
heparin-associated bleeding increases with
concomitant thrombolytics or glycoprotein IIb-
IIIa antagonists, these agents frequently are
coadministered.17 Extrapolating data from
heparin studies enables identification of situa-
tions that may place patients receiving drotrecogin
alfa (activated) at a greater risk of bleeding.
However, such situations in most cases should
not be viewed as absolute contraindications.
Similar to the situation with other anticoagulants
(heparin, warfarin), the individual risks and
potential benefits must be weighed carefully for
each patient.
Admixture Preparation Considerations
The recommended dosage regimen for
drotrecogin alfa (activated) is 24 µg/kg/hour to
be given as a continuous intravenous infusion for
96 hours.5, 20 The dosage should be based on the
patient’s total body weight at the start of therapy.
To minimize administration errors and drug
waste, the storage, preparation, and labeling of
drotrecogin alfa (activated) should be under the
strict supervision of a pharmacist.  The reconsti-
tution and admixture of drotrecogin alfa
(activated) must use an aseptic technique.  In
institutions where 24-hour pharmacy services are
not available, an alternative plan to prepare the
agent should be in place (e.g., on-call pharmacist).
Drotrecogin alfa (activated) reconstitution and
administration guidelines are depicted in
Appendix 2.
Dilution
When using an intravenous infusion pump,
drotrecogin alfa (activated) admixtures must be
reconstituted with 0.9% sodium chloride
injection (United States Pharmacopeia), typically
to a final concentration of 100–200 µg/ml.5, 20
Drotrecogin alfa (activated) cannot be
administered undiluted or using the intravenous
push method.  When administering low
concentrations at low flow rates (i.e., < 200
µg/ml at < 5 ml/hr), it is recommended that the
infusion set be primed for approximately 15
minutes at a flow rate of 5 ml/hour.5, 20
Fluid Load
Occasionally, critically ill patients have a fluid
and sodium restriction.  To minimize the amount
of admixture fluid used in these rare instances,
we suggest admixing drotrecogin alfa (activated)
in the most concentrated solutions allowable.
The dosing guidelines in Appendix 3 are based
exclusively on the administration of drotrecogin
alfa (activated) 200 µg/ml by an infusion pump.
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For example, a patient weighing 70 kg requires
drotrecogin alfa (activated) 10 mg every 6 hours
(40 mg/day).  At a concentration of 100 µg/ml,
each 10-mg dose would require 100 ml, which
would result in 400 ml/day of normal saline.  At a
concentration of 200 µg/ml, each 10-mg dose
would require 50 ml, totaling 200 ml/day of
normal saline.  The net savings of 200 ml/day of
normal saline may be significant in patients
requiring several drugs in large volume
admixtures.  Furthermore, when using a syringe
pump to administer drotrecogin alfa (activated),
concentrated solutions of up to 1000 µg/ml are
allowable and greater fluid savings are realized.
Although not all patients will require a
concentrated solution, using several different
concentrations is error prone, and a standard
concentration is recommended.  A drotrecogin
alfa (activated) dosing chart with infusion rates
(ml/hr) based on dosage and the patient’s weight,
using a drug concentration of 200 µg/ml, is
provided in Appendix 3.
Sodium Load
High sodium loads can be detrimental in
certain critically ill patients (e.g., patients with
pulmonary edema, renal failure, cirrhosis with
ascites, or chronic heart failure).  In these
instances, sodium chloride intake should be
restricted to no more than 1–2 g/day.
Drotrecogin alfa (activated) 5- and 20-mg vials
contain 40.3 mg and 158.1 mg of sodium
chloride, respectively.5 A patient weighing 70 kg
who receives drotrecogin alfa (activated) at a
dosage of 10 mg/100 ml every 6 hours, using a
concentration of 100 µg/ml in normal saline will
add a sodium load of 1738 mg (322 mg from
drug and 1416 mg from normal saline).  In the
critical care setting where high sodium
load–containing drugs (e.g., metronidazole,
piperacillin, and ticarcillin) are administered
routinely, the cumulative sodium load can be
significant.  One strategy to minimize sodium
load is to admix drotrecogin alfa (activated) with
dextrose solutions rather than sodium chloride.
However, because stability data do not exist, this
practice is not recommended.  Clinicians should
be cognizant of drotrecogin alfa (activated)’s
sodium load and should consider concentrated
solutions in sodium-restricted patients.
Minimizing Drug Waste
To maximize drotrecogin alfa (activated) cost
savings by minimizing waste, it is permissible to
develop preparation guidelines that are based on
patients’ actual body weight, that use multiple
dosing intervals such as every 6-, 8-, and 12-hour
continuous infusions, and by purchasing 5-mg
vials rather than 20-mg vials.  Unfortunately, no
one dosage interval is cost-effective for all patient
weights.  For example, at a dosage of 24
µg/kg/hour, a patient weighing 70 kg will require
drotrecogin alfa (activated) 40 mg/day.  A 6-hour
interval of 10 mg will require 2 vials/dose, 8
vials/day, and 32 vials for the 96-hour
treatment—at a cost of $6720.  Comparatively,
for the same patient weighing 70 kg, an 8-hour
interval of 13.44 mg will require 2.5 vials/dose, 9
vials/day, and 36 vials for the 96-hour
treatment—at a cost of $7560.  Owing to the
drug waste in the every-8-hour regimen
compared with no waste in the every-6-hour
regimen, a cost savings of $840/patient can be
realized.  Although, the use of different dosing
intervals will limit drug waste and realize cost
savings, a higher risk of drug error may prevail.
One practical question that often arises is
whether the milligram dose of drotrecogin alfa
(activated) can be rounded off?  This question
arises in part because of the agent’s limited
stability, availability in only 5- and 20-mg vials,
and acquisition cost.  For example, a patient
weighing 90 kg would require 25.9 mg of
drotrecogin alfa (activated) over a 12-hour
period.  Since drotrecogin alfa (activated) is
available in 20-mg vials, the question arises
whether to round down the dose to 20 mg
administered as a continuous infusion over 12
hours (i.e., 18.5 µg/kg/hr) or to alter the dosing
interval (e.g., 24 µg/kg/hr for 8 hrs = 17.3
mg/dose of drotrecogin alfa [activated]).
Although the former approach of rounding down
the dose of drotrecogin alfa (activated) may
appear appealing, the phase II dose-ranging study
demonstrated that when the dose was decreased
from 24 µg/kg/hour to 18 µg/kg/hour, the effect
on the clotting and inflammatory markers
waned.21 However, the effect of drotrecogin alfa
(activated) on the clotting and inflammatory
markers increased as the dose increased from 24
to 30 µg/kg/hour.  From this information, we can
infer that decreasing the dosage to a value below
the minimum dosage that was effective in
decreasing mortality is not justifiable.
Successful Implementation of the Guidelines
Clearly, a multitude of factors must be
considered when developing drotrecogin alfa
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(activated) administration guidelines.  Although
the available evidence must be used to support
the decision-making process, this issue should
not be evaluated in a vacuum, but all the
evidence and relevant data should be considered.
The available evidence regarding drotrecogin alfa
(activated) should be integrated with current
data for other products administered in the
intensive care unit in order to develop a guide to
realistic drotrecogin alfa (activated) therapy that
optimizes potential outcomes, by targeting
patients who are likely to benefit from the agent
while taking into consideration the risk of
bleeding.
Successful implementation of drotrecogin alfa
(activated) administration guidelines requires
education of all the physicians, pharmacists, and
nurses involved in the management of sepsis.
Everyone should understand both the guidelines
and the process used to prescribe the drug.
Because of the complexity of the disease state and
the drug administration guidelines, in addition to
the agent’s high acquisition cost, many
institutions have elected to designate authorized
prescribers.  If this approach is chosen as part of
the implementation process, the list of
authorized prescribers must be identified and a
process for obtaining the agent at anytime must
be outlined, despite the potential availability of
the authorized prescriber (e.g., in the middle of
the night).  The authorized prescriber or
gatekeeper must have a thorough understanding
of the management of severe sepsis and the
administration guidelines for drotrecogin alfa
(activated).
One step that may facilitate implementation of
the guidelines is the use of an order form
specifically designed for prescribing drotrecogin
alfa (activated), as depicted in Appendix 1.  Such
tools can serve many purposes, including
educating clinicians on drotrecogin alfa
(activated) guidelines, aiding the prescribing
process (e.g., checklists), and quality assurance.
After the guidelines are implemented, periodic
review of the process and appropriate
administration of drotrecogin alfa (activated)
should be evaluated in a quality improvement
manner.
The drotrecogin alfa (activated) guidelines are
the first step in optimizing the management of
sepsis.  Although many institutions may view
such guidelines as a process to control drug
administration, one should target optimizing the
management of severe sepsis and develop other
aids that will address additional aspects of the
management of sepsis.  In general, the guidelines
must facilitate optimization of drug therapy and
should not be viewed as overwhelming obstacles
to drug therapy.  Developing clear guidelines that
are based on evidence, outlining a specific
process to facilitate optimization of therapy, and
educating all parties involved are tantamount to
ensuring that the benefits of drotrecogin alfa
(activated) are maximized.  Clinicians should
recognize these guidelines as an attempt to
facilitate appropriate prescribing and not as a
barrier to drug therapy.
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Appendix 1.  Drotrecogin alfa (activated) (Xigris) Order Form
The following criteria for drotrecogin alfa (activated) therapy are based on the Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis (PROWESS) study inclusion and exclusion criteria, and U.S. Food and Drug
Administration (FDA) guidelines for patients who develop sepsis with sepsis-induced organ dysfunction.  Once the order form
is completed and all criteria are met and approved by the designated physician, there is a 48-hour window in which drotrecogin
alfa (activated) should be administered.
I. Drotrecogin alfa (activated) is indicated for reducing mortality in adult patients with severe sepsis, defined as a known or
suspected infection, who meet the criteria for the modified systemic inflammatory response syndrome (SIRS), have at least two
organ or system dysfunctions, and have a high risk of death.
A. Patient has a known or suspected infection, defined as one or more of the following:
o Positive culture.
o White blood cells in a normally sterile body fluid.
o Perforated viscus.
o Radiographic evidence of pneumonia along with purulent sputum.
o A syndrome associated with a high risk of infection (e.g., ascending cholangitis).
B. Patient has modified SIRS, defined as three or more of the following signs:
o Core temperature of ‡ 38°C (‡ 100.4°F) or ≤ 36°C (≤ 96.8°F).
o Heart rate of ‡ 90 beats/minute except in patients with a medical condition known to increase the heart rate (e.g.,
dysrhythmias, hyperthyroidism, chronic heart failure, anemia) or in those receiving treatment that would prevent
tachycardia (e.g., b-blockers, verapamil, diltiazem, a2 agonists [clonidine, methyldopa, guanfacine, guanabenz],
digoxin, antidysrhythmics, opioids, carbamazepine [in those aged ‡ 50 yrs]).
o Respiratory rate of ‡ 20 breaths/minute or a partial pressure of carbon dioxide (PCO2) of ≤ 32 mm Hg, or mechanical
ventilation for an acute respiratory process.
o White blood cell count of ‡ 12 x 103/mm3 or ≤ 4 x 103/mm3, or a differential showing > 10% bands.
C. Patient has evidence of organ dysfunction, defined as two or more of the following:
o Cardiovascular (one or more of the following):
o Arterial systolic blood pressure (SBP) ≤ 90 mm Hg or mean arterial pressure (MAP) of ≤ 70 mm Hg for at least 1 hour
despite adequate fluid resuscitation or adequate intravascular volume status.
o Vasopressor therapy in an attempt to maintain SBP at ‡ 90 mm Hg or MAP at ‡ 70 mm Hg.
o Renal:
o Urine output < 0.5 ml/kg/hour for at least 1 hour despite adequate fluid resuscitation.
o Respiratory (one or more of the following):
o Ratio of partial pressure of oxygen:fraction of inspired oxygen (PaO2:FIO2) ≤ 250 in the presence of other organ
dysfunction.
o Hematologic (one or more of the following):
o Platelet count < 80 x 103/mm3 in the preceding 3 days.
o Platelet count reduction by ‡ 50% in the preceding 3 days.
o Unexplained metabolic acidosis (one or more of the following):
o pH ≤ 7.3 or base deficit ‡ 5 mmol/L.
o Base deficit ‡ 5 mmol/L along with plasma lactate level > 1.5 times the upper limit of normal.
II. Drotrecogin alfa (activated) increases the risk of bleeding.  According to the Xigris manufacturer’s information, the drug is
contraindicated in clinical scenarios in which bleeding can be associated with a high risk of morbidity or mortality.
Absolute contraindications, defined as one or more of the following:
o Active internal bleeding.
o Hemorrhagic stroke within the past 3 months.
o Intracranial or intraspinal surgery or severe head trauma within the past 2 months.
o Trauma with an increased risk of life-threatening bleeding.
o Presence of an epidural catheter.
o Intracranial neoplasm or mass lesion or evidence of cerebral herniation.
o Known sensitivity to drotrecogin alfa (activated) or any component of this product.
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Appendix 1.  Drotrecogin alfa (activated) (Xigris) Order Form (continued)
III. The most common serious adverse effect associated with drotrecogin alfa (activated) is bleeding.  Patients with clinical
scenarios that may increase the risk of bleeding were excluded from the PROWESS trial; however, the Xigris manufacturer’s
information does not list these scenarios as contraindications, but does include them in the Warnings section.  It is plausible
that administering drotrecogin alfa (activated) in patients with clinical scenarios that may increase the risk of bleeding may lead
to a higher frequency of bleeding episodes.  Hence, the clinician should weigh the benefits of drotrecogin alfa (activated)
carefully against the risks in patients with the following scenarios.
Warnings as noted in the manufacturer’s information include the following: 
o Concurrent therapy with heparin at dosages that increase the activated partial thromboplastin time to ‡ 1.5 times the
control (‡ 15 U/kg/hr).
o Initial platelet count < 30 x 103/mm3, even if the platelet count is increased after transfusions.
o Gastrointestinal bleeding within the past 6 weeks.
o International normalized ratio greater than 3.
o Administration of oral anticoagulants within the previous 7 days unless INR < 3.
o Administration of aspirin > 650 mg/day or other platelet inhibitors (e.g., clopidogrel, dipyridamole, ticlopidine) within
the past 7 days.
o Administration of glycoprotein IIb-IIIa inhibitors within the past 7 days.
o Administration of thrombolytics within the past 3 days (catheter clearance doses are not considered a warning).
o Ischemic stroke within the past 3 months.
o Intracranial arteriovenous malformation or aneurysm.
o Known bleeding diathesis.
o Chronic severe hepatic disease.
o Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage
because of its location.
IV. In the PROWESS trial, patients were excluded for specific criteria, including a futile diagnosis, increased risk of bleeding,
and a known hypercoagulable condition.  However, these specific criteria are not listed in the Xigris manufacturer’s information.
Hence, the clinician should weigh carefully the benefits of drotrecogin alfa (activated) against the risks in patients with the
following scenarios.
Exclusion criteria, as noted in the PROWESS trial: 
o Age < 18 years.
o Weight > 135 kg (these patients were excluded to ensure adequate supply of drotrecogin alfa [activated]).
o Surgery requiring general or spinal anesthesia within 12 hours before the infusion.
o Potential need for surgery during the infusion.
o Known hypercoagulable condition including the following:
o Resistance to activated protein C.
o Hereditary deficiency of protein C, protein S, or antithrombin III.
o Presence of anticardiolipin antibody.
o Presence of antiphospholipid antibody.
o Presence of lupus anticoagulant.
o Presence of homocystinemia.
o Documented or highly suspected deep vein thrombosis or pulmonary embolism within the past 3 months.
o Patient’s family, physician, or both not in favor of aggressive treatment of patient, or presence of an advanced directive to
withhold life-sustaining treatment.
o Patients not expected to survive 28 days because of an uncorrectable medical condition such as poorly controlled
neoplasm or other end-stage disease.
o Moribund state in which death was perceived as imminent.
o Human immunodeficiency virus infection in association with a last known CD4 count of ≤ 50/mm3.
o History of bone marrow, lung, liver, pancreas, or small-bowel transplantation.
o Chronic renal failure requiring hemodialysis or peritoneal dialysis. 
o Acute pancreatitis with no established source of infection.
o Any of the following treatment regimens (in addition to the ones listed under warnings):
o Low-molecular-weight heparin at a higher dosage than recommended for prophylaxis within the previous 12 hours.
o Antithrombin III at a dose of more than 10,000 U within the previous 12 hours.
o Protein C administration within the previous 24 hours.
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Appendix 2.  Drotrecogin alfa (activated) (Xigris) Reconstitution and Administration Guidelines
Stability
• The intravenous solution should be prepared immediately on reconstitution of drotrecogin alfa (activated) vials because
they do not contain any antibacterial preservative.
• If the vial is not reconstituted immediately, it may be stored at room temperature at 15–30°C (59–86°F) but must be
used within 3 hours.
• Saline solutions contain an unspecified amount of zinc that may chelate with drotrecogin alfa (activated), thus the
stability of drotrecogin alfa (activated) intravenous solutions is limited.  At room temperature, after the intravenous
solution of drotrecogin alfa (activated) is prepared, administration must be completed within 14 hours.
• Drotrecogin alfa (activated) admixtures may be stored in a refrigerator at 2–8°C (36–46°F) for up to 12 hours.  The total
in-use time after drotrecogin alfa (activated) reconstitution and refrigeration (maximum of 12 hrs) and administration at
room temperature should not exceed 24 hours.
• The infusion bag should be inspected visually for foam production before administration.
• Avoid exposing drotrecogin alfa (activated) solutions to heat or direct sunlight.
• Covering the infusion bag to protect from light is unnecessary.  However, if the drotrecogin alfa (activated) solution will
be exposed to direct sunlight, it should be covered with a brown bag or aluminum foil.
• Drotrecogin alfa (activated) is a glycoprotein of approximately 55-kD molecular weight; excessive agitation may
denature the glycoprotein.  Drotrecogin alfa (activated) infusion bags should be handled gently and should not be
transported by means of mechanical delivery systems.
Dilution
• Preparation of drotrecogin alfa (activated) should take place with an aseptic technique.
• When using an intravenous infusion pump to administer the drug, the solution of reconstituted drotrecogin alfa
(activated) is diluted with 0.9% sodium chloride injection (United States Pharmacopeia [USP]) to a final concentration of
100–200 µg/ml.  The stability of drotrecogin alfa (activated) solutions that are more dilute (e.g., due to adsorption to
tubing) or concentrated (e.g., due to degradation) has not been studied; excessive dilution or concentration therefore is
not recommended.
• When using a syringe pump to administer the drug, the solution of reconstituted drotrecogin alfa (activated) is diluted
with 0.9% sodium chloride injection (USP) to a final concentration of 100–1000 µg/ml.  When administering
drotrecogin alfa (activated) at concentrations less than approximately 5 ml/hour, the infusion rate must be primed for
approximately 15 minutes at a flow rate of approximately 5 ml/hour.
Administration and Compatibility
• No compatibility studies have been completed with intravenous drugs that are administered routinely in a critical care
setting.  Hence, drotrecogin alfa (activated) should be administered by means of a dedicated intravenous line or a
dedicated lumen of a multilumen central venous catheter.
• The only solutions that can be coadministered through the same line as that used for a drotrecogin alfa (activated)
intravenous solution (e.g., a y-line) are 0.9% sodium chloride injection (USP), Ringer’s lactate injection, dextrose, or
dextrose and saline mixtures with up to 40 mEq/L of potassium chloride.
• The dedicated line or lumen may be used for other reasons before or after drotrecogin alfa (activated) infusion, if flushed
with 30–60 ml of 0.9% sodium chloride injection (USP), dextrose, or dextrose and saline mixtures.
• No incompatibilities have been observed between drotrecogin alfa (activated) and glass infusion bottles or infusion bags
and syringes made of polyvinylchloride, polyethylene, polypropylene, or polyolefin.
Vial Reconstitution
Drotrecogin alfa (activated) 5-mg and 20-mg vials must be reconstituted with 2.5 ml and 10 ml, respectively, of sterile water for
injection (USP), resulting in a concentration of approximately 2 mg/ml.
Step 1:  Slowly add the corresponding amount of sterile water for injection (USP) to the vial and avoid shaking or inverting
the vial.
Step 2:  Gently swirl each vial until the powder is completely dissolved.
Infusion Bag Preparation
The reconstituted vials must be diluted further with 0.9% sodium chloride injection  (USP), resulting in a final concentration of
100–200 µg/ml.  All doses require a 100-ml intravenous infusion bag.
Step 1:  Slowly withdraw the appropriate prescribed amount of the reconstituted drotrecogin alfa (activated) solution from
the vial.
Step 2:  Add the reconstituted drotrecogin alfa (activated) solution to a 100-ml infusion bag of 0.9% sodium chloride
injection (USP) by directing the stream to the side of the bag to minimize agitation of the solution.
Step 3:  Gently invert the infusion bag to obtain a homogeneous solution.
Adapted from references 5 and 20.
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Appendix 3.  Drotrecogin alfa (activated) (Xigris) Dosing Chart
The dosage of drotrecogin alfa (activated) for all adult patients is 24 µg/kg/hour for 96 hours administered as a continuous
infusion.  The drotrecogin alfa (activated) dosage is based on actual body weight on the first day that therapy is started.  The
dosage should not be adjusted despite increases or decreases in body weight.  The infusion rates listed below provide the
appropriate dosage based on the corresponding weight and at a standard concentration of 200 µg/ml (20 mg/100 ml).
Weight Infusion Rate Weight Infusion Rate Weight Infusion Rate Weight Infusion Rate
(kg) (ml/hr) (kg) (ml/hr) (kg) (ml/hr) (kg) (ml/hr)
30 3.6 60 7.2 90 10.8 120 14.4
31 3.7 61 7.3 91 10.9 121 14.5
32 3.8 62 7.4 92 11.0 122 14.6
33 4.0 63 7.6 93 11.2 123 14.8
34 4.1 64 7.7 94 11.3 124 14.9
35 4.2 65 7.8 95 11.4 125 15.0
36 4.3 66 7.9 96 11.5 126 15.1
37 4.4 67 8.0 97 11.6 127 15.2
38 4.6 68 8.2 98 11.8 128 15.4
39 4.7 69 8.3 99 11.9 129 15.5
40 4.8 70 8.4 100 12.0 130 15.6
41 4.9 71 8.5 101 12.1 131 15.7
42 5.0 72 8.6 102 12.2 132 15.8
43 5.2 73 8.8 103 12.4 133 16.0
44 5.3 74 8.9 104 12.5 134 16.1
45 5.4 75 9.0 105 12.6 135a 16.2
46 5.5 76 9.1 106 12.7
47 5.6 77 9.2 107 12.8
48 5.8 78 9.4 108 13.0
49 5.9 79 9.5 109 13.1
50 6.0 80 9.6 110 13.2
51 6.1 81 9.7 111 13.3
52 6.2 82 9.8 112 13.4
53 6.4 83 10.0 113 13.6
54 6.5 84 10.1 114 13.7
55 6.6 85 10.2 115 13.8
56 6.7 86 10.3 116 13.9
57 6.8 87 10.4 117 14.0
58 7.0 88 10.6 118 14.2
59 7.1 89 10.7 119 14.3
aPublished data are not available relative to the dosing of drotrecogin alfa (activated) in patients weighing more than 135 kg.
Adapted from references 5 and 20.
